[go: up one dir, main page]

WO2005007137A3 - Ambroxolhaltige tabletten - Google Patents

Ambroxolhaltige tabletten Download PDF

Info

Publication number
WO2005007137A3
WO2005007137A3 PCT/EP2004/007849 EP2004007849W WO2005007137A3 WO 2005007137 A3 WO2005007137 A3 WO 2005007137A3 EP 2004007849 W EP2004007849 W EP 2004007849W WO 2005007137 A3 WO2005007137 A3 WO 2005007137A3
Authority
WO
WIPO (PCT)
Prior art keywords
tablets containing
ambroxol
containing ambroxol
pharmaceutically acceptable
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/007849
Other languages
English (en)
French (fr)
Other versions
WO2005007137A8 (de
WO2005007137A2 (de
Inventor
Anja Kohlrausch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10360086A external-priority patent/DE10360086A1/de
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to CA002532485A priority Critical patent/CA2532485A1/en
Priority to EP04763241A priority patent/EP1648423A2/de
Publication of WO2005007137A2 publication Critical patent/WO2005007137A2/de
Publication of WO2005007137A3 publication Critical patent/WO2005007137A3/de
Anticipated expiration legal-status Critical
Publication of WO2005007137A8 publication Critical patent/WO2005007137A8/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft den Wirkstoff Ambroxol oder eines seiner pharmakologisch verträglichen Salze enthaltende Tabletten, wobei der Ambroxolgehalt pro Tablette in einem Bereich von 250 bis 1000 mg liegt.
PCT/EP2004/007849 2003-07-16 2004-07-15 Ambroxolhaltige tabletten Ceased WO2005007137A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002532485A CA2532485A1 (en) 2003-07-16 2004-07-15 Tablets containing ambroxol
EP04763241A EP1648423A2 (de) 2003-07-16 2004-07-15 Ambroxolhaltige tabletten

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10332458.5 2003-07-16
DE10332458 2003-07-16
DE10360086A DE10360086A1 (de) 2003-07-16 2003-12-20 Ambroxolhaltige Tabletten
DE10360086.8 2003-12-20

Publications (3)

Publication Number Publication Date
WO2005007137A2 WO2005007137A2 (de) 2005-01-27
WO2005007137A3 true WO2005007137A3 (de) 2005-04-28
WO2005007137A8 WO2005007137A8 (de) 2006-09-21

Family

ID=34081653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007849 Ceased WO2005007137A2 (de) 2003-07-16 2004-07-15 Ambroxolhaltige tabletten

Country Status (4)

Country Link
US (1) US20050027012A1 (de)
EP (1) EP1648423A2 (de)
CA (1) CA2532485A1 (de)
WO (1) WO2005007137A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1976488A4 (de) * 2006-01-12 2010-02-10 Wockhardt Ltd Zusammensetzungen aus alfuzosin mit verzögerter freisetzung
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP4151218A1 (de) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, ein xanthinderivat als dpp-4-inhibitor zur verwendung bei der behandlung von sirs und/oder sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
TW201521794A (zh) * 2013-11-12 2015-06-16 Daiichi Sankyo Co Ltd 錠劑
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN108113971B (zh) * 2016-11-28 2021-12-28 北京科信必成医药科技发展有限公司 一种盐酸氨溴索掩味制剂及其制备方法
CN112745251B (zh) * 2019-10-31 2023-10-27 华创合成制药股份有限公司 一种治疗祛痰化合物及其制备方法和用途
CN112773769B (zh) * 2019-11-07 2022-11-15 烟台东诚药业集团股份有限公司 一种盐酸氨溴索分散片及其制法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1178034A (en) * 1966-05-10 1970-01-14 Thomae Gmbh Dr K Hydroxy-Cyclohexylamines
EP0138020A2 (de) * 1983-09-17 1985-04-24 Dr. Karl Thomae GmbH Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat
WO2003061642A1 (de) * 2002-01-25 2003-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Verwendung von ambroxol zur behandlung von chronischen schmerzen, cerebralen exzitotoxizitätsbedingten störungen und kardialen arrhythmien

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1178034A (en) * 1966-05-10 1970-01-14 Thomae Gmbh Dr K Hydroxy-Cyclohexylamines
EP0138020A2 (de) * 1983-09-17 1985-04-24 Dr. Karl Thomae GmbH Antiadhäsive Prophylactica und Arzneimittel enthaltend ein sekretolytisch wirksames Benzylaminderivat
WO2003061642A1 (de) * 2002-01-25 2003-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Verwendung von ambroxol zur behandlung von chronischen schmerzen, cerebralen exzitotoxizitätsbedingten störungen und kardialen arrhythmien

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"AMBROXOL BEI HALSSCHMERZEN", DEUTSCHE APOTHEKER ZEITUNG, DEUTSCHER APOTHEKER ZEITUNG, STUTTGART, DE, vol. 142, no. 17, 25 April 2002 (2002-04-25), pages 45 - 47, XP001147779, ISSN: 0011-9857 *
ROTE LISTE SERVICE GMBH (ED): "Rote Liste 2002", 2002, ROTE LISTE 2002. ARZNEIMITTELVERZEICHNIS FUER DEUTSCHLAND (EINSCHLIESLICH EU - ZULASSUNGEN UND BESTIMMTER MEDIZINPRODUKTE), AULENDORF : EDITIO CANTOR, DE, PAGE(S) 5389, ISBN: 3-87193-252-3, XP002247690 *

Also Published As

Publication number Publication date
WO2005007137A8 (de) 2006-09-21
CA2532485A1 (en) 2005-01-27
US20050027012A1 (en) 2005-02-03
EP1648423A2 (de) 2006-04-26
WO2005007137A2 (de) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2005007137A8 (de) Ambroxolhaltige tabletten
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
EP0960621A3 (de) Pharmazeutische Zusammensetzungen enthaltend sildenafil
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
WO2001078680A3 (en) Pharmaceutical compositions comprising fluvastatin
MXPA03007712A (es) Sales farmaceuticas.
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2004058837A3 (de) Ampholytisches copolymer und dessen verwendung
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
AU2003286994A1 (en) Modified release pharmaceutical composition
EP1419785A4 (de) Arzneimittel mit einem chymase-hemmer und einem ace-hemmer als wirkstoffe
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
AR038206A1 (es) Composicion farmaceutica dispersable oralmente de ivabradina
WO2005051350A3 (en) Water dispersible tablet
WO2005065047A3 (en) Stable oral composition containing desloratadine
AR038305A1 (es) Composicion farmaceutica dispersable oralmente de perindopril
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
AU2003246566A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004763241

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2532485

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006519877

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004763241

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004763241

Country of ref document: EP